Comparison of biochemical markers of bone remodelling in the assessment of the effects of alendronate on bone in postmenopausal osteoporosis

Clinica Chimica Acta

Volumn 288, Issue 1-2, 1999, Pages 121-135

  Stepan J J ^a   Vokrouhlicka J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Alendronate; Biochemical markers; Bone mineral density; Collagen I; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; CREATININE; HYDROXYPROLINE; OSTEOCALCIN; PLACEBO; PROCOLLAGEN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PLACEBOS; POSTMENOPAUSE;

EID: 0344069654     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(99)00151-5     Document Type: Article

References (16)

1. Kanis JA, Melton III LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
2. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late-postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
3. Balena R, Toolan BC, Shea M et al. The effects of 2-year treatment with the amino-bisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993;92:2577-86.
4. Liberman UA, Weiss SR, Bröll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
5. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
6. Ensrud KE, Black DM, Palermo L et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997;157:2617-24.
7. McClung M, Clemmesen B, Daifotis A et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Ann Intern Med 1998;128:253-61.
8. Hosking D, Chilvers CE, Christiansen C et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338:485-92.
9. Wahner HW, Steiger P, von Stetten E. Instruments and measurement techniques. In: Wahner HW, Fogelman I, editors, The evaluation of osteoporosis: dual energy X-ray absorptiometry in clinical practice, London: Martin Dunitz, 1995, pp. 14-34.
10. Harris ST, Gertz BJ, Genant HK et al. The effect of short-term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993;76:1399-406.
11. Pols HAP, Felsenberg D, Hanley D et al. A multinational randomized trial of the effects of alendronate on bone mineral density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporosis Int 1999;9:461-8.
12. Stepan J, Volek V, Kolar J. A modified inactivation-inhibition method for determining the serum activity of alkaline phosphatase isoenzymes. Clin Chim Acta 1967;69:1-9.
13. Dubovsky J, Hrba J, Pacovsky V. Acute effects of calcium infusion on hydroxyproline. Clin Chim Acta 1967;17:107-10.
14. Moro L, Modricky C, Stagni N, Vittur F, de Bernard B. High performance liquid chromatographic analysis of urinary hydroxylysyl-glycosides as indicators of collagen turnover. Analyst 1984;109:1621-2.
15. Hansen MA, Kirsten O, Riis BJ, Christiansen C. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 years study. Br Med J 1991;303:961-4.
16. Garnero P, Darte C, Delmas PD. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 1999;24:603-9.